Sandoz's Biosimilar Shows Similarity to Amgen's Neupogen

December 8, 2014
Agnes Shanley

Agnes Shanley is senior editor of BioPharm International.

Sandoz announces their version of filgrastim, a follow-on biologic for the treatment of neutropenia, is as safe and effective as Amgen's Neupogen.